Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012)

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.397
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Php353 - Romanian Experience With Managed Entry Agreements for Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adoption of Managed Entry Agreements in Established and Emerging Markets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

What Principles Should Govern the Use of Managed Entry Agreements?

International Journal of Technology Assessment in Health Care
Health Policy
2011English

PHP46 Market Uptake of Orphan Drugs – A European Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Managed Entry Agreements (MEA): Analysis of the Current Situation in Middle East and North Africa

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Php249 - Are Traditional Managed Entry Agreements Suitable for Potentially, Curative Gene/Cell Therapies?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy135 - Access to Orphan Drugs – Regulation Within the European Law

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy188 - Use of Managed Entry Agreements in Inflammatory Disorders Among Key Health Technology Assessment Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy165 - Price Differences for Orphan Drugs Across the Eu-5 Countries: A Comparative Assessment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy